Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous

PURPOSE: To report 2 eyes of a patient which developed vitreomacular traction (VMT) 1 month after intravitreal bevacizumab (IVB) injection. MATERIALS AND METHODS: A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB. RESULTS: Her initial visual acuity (VA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozsutcu, Mustafa, Gulkilik, Gokhan, Ayintap, Emre, Altinisik, Muhammed, Demirci, Goktug, Aras, Cengiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: January, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573800/
https://www.ncbi.nlm.nih.gov/pubmed/23467022
http://dx.doi.org/10.1159/000342873
_version_ 1782259504856956928
author Ozsutcu, Mustafa
Gulkilik, Gokhan
Ayintap, Emre
Altinisik, Muhammed
Demirci, Goktug
Aras, Cengiz
author_facet Ozsutcu, Mustafa
Gulkilik, Gokhan
Ayintap, Emre
Altinisik, Muhammed
Demirci, Goktug
Aras, Cengiz
author_sort Ozsutcu, Mustafa
collection PubMed
description PURPOSE: To report 2 eyes of a patient which developed vitreomacular traction (VMT) 1 month after intravitreal bevacizumab (IVB) injection. MATERIALS AND METHODS: A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB. RESULTS: Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively. CONCLUSION: In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy.
format Online
Article
Text
id pubmed-3573800
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-35738002013-03-05 Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous Ozsutcu, Mustafa Gulkilik, Gokhan Ayintap, Emre Altinisik, Muhammed Demirci, Goktug Aras, Cengiz Case Rep Ophthalmol Published online: January, 2013 PURPOSE: To report 2 eyes of a patient which developed vitreomacular traction (VMT) 1 month after intravitreal bevacizumab (IVB) injection. MATERIALS AND METHODS: A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB. RESULTS: Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively. CONCLUSION: In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy. S. Karger AG 2013-01-22 /pmc/articles/PMC3573800/ /pubmed/23467022 http://dx.doi.org/10.1159/000342873 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: January, 2013
Ozsutcu, Mustafa
Gulkilik, Gokhan
Ayintap, Emre
Altinisik, Muhammed
Demirci, Goktug
Aras, Cengiz
Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title_full Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title_fullStr Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title_full_unstemmed Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title_short Intravitreal Bevacizumab May Increase Diabetic Macular Edema in Eyes with Attached Posterior Vitreous
title_sort intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous
topic Published online: January, 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573800/
https://www.ncbi.nlm.nih.gov/pubmed/23467022
http://dx.doi.org/10.1159/000342873
work_keys_str_mv AT ozsutcumustafa intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous
AT gulkilikgokhan intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous
AT ayintapemre intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous
AT altinisikmuhammed intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous
AT demircigoktug intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous
AT arascengiz intravitrealbevacizumabmayincreasediabeticmacularedemaineyeswithattachedposteriorvitreous

Ejemplares similares